about
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesA data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.Multi-perspective quality control of Illumina exome sequencing data using QC3.Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data MiningTransforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancerRadiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.Subtyping of triple-negative breast cancer: implications for therapyDetection of internal exon deletion with exon Del.Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive valueA Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerGeneration of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.Clinical implications of molecular heterogeneity in triple negative breast cancer.Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancerTargeting prostate cancer based on signal transduction and cell cycle pathways.Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.SPARCL1 suppresses metastasis in prostate cancer.Senescence-associated exosome release from human prostate cancer cells.Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.Triple-negative breast cancer: molecular subtypes and new targets for therapy.p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library.Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control.Practicality of identifying mitochondria variants from exome and RNAseq data.Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
P50
Q24645668-33E03DA9-2DE7-42A1-A3C2-942AC21E8944Q29617680-2421C4A6-C12A-46E6-A98E-04A38F3F2A69Q30587056-2A2F6EEB-87E9-4191-88A1-AC2E8C564063Q30794236-CFC86466-CC5E-4715-9EBD-93A8F8529E8FQ30985595-39A45DE3-78F9-4CA9-8C72-1EBA9B06F081Q31138624-E9DFE322-EFAC-4670-A107-554BB4FDFC35Q33892756-E42FE377-2AEF-450B-83D8-D4DC59974BCBQ33896844-D4A1ACCE-BE37-429E-B870-1E1D717C11B8Q33926909-7DC3E8AD-47F9-4AA5-A43F-6AA411C9FD3EQ34048144-5453DA2B-AAC8-433C-9EDB-97D91FB64F39Q34734477-93535357-6D59-4A68-80B2-ACE5D2DD09ADQ35342121-284749CB-4841-41CD-B978-69E7F53B6727Q35503492-9BA02B1B-42FB-43BD-8025-56FE63259C66Q35627868-817476D2-558D-4ED2-8D1D-439B08DEC1DAQ35631181-D1E9A8C6-A686-4200-AE30-8C79AF04E47CQ35933373-C20BF9AB-7C77-4768-9EB1-508AD6C8D19EQ36054418-62A7D578-3B15-420A-8D78-768F9D2AF8EEQ36142926-06B20257-B0AD-402C-9B93-7091F37513ACQ36271396-F719F310-DBD5-4399-9E5C-F561AEFEA47BQ36847243-5D8C8117-D35C-4127-B08D-B7CA3A3A0BFDQ36995054-C81DDD0C-B425-40CF-8E8D-EDFE8C5630A9Q37331720-997439C4-B36E-40FA-9F02-7908921173C5Q37337322-095F3327-EA45-4E79-9958-7BE425A9083EQ37352797-B8DD07C3-4018-44E5-8FAC-098F2C11FE4DQ37624234-BDA353E5-F1CA-4A31-AFB8-4EED57367CE7Q38768199-59BE69D5-4491-467A-9CC9-E96DBFCA322DQ39004544-5CCCD89E-482C-4822-B4DB-B686CB189B7EQ39237016-9EABE9AF-989A-40EC-9294-3DEEDC15544AQ40154931-5EDB476D-BAB8-4BA3-8AF9-5CAAB325352AQ40160733-3078FAD8-265D-459C-8A4F-3A387A58263BQ40349181-3C8CCEBA-A56E-4996-8196-16CEDB5B5205Q42875652-28FB8746-2AB9-4ED4-ADBB-D52EE997779BQ45750691-1EB2F5CB-2D30-461E-AAF9-FF637C14887DQ90244228-E4D752C2-00AB-4B5A-8624-6F5BEBE067A0
P50
description
medical researcher
@en
onderzoeker
@nl
հետազոտող
@hy
name
Brian D Lehmann
@ast
Brian D Lehmann
@es
Brian D Lehmann
@nl
Brian D. Lehmann
@en
type
label
Brian D Lehmann
@ast
Brian D Lehmann
@es
Brian D Lehmann
@nl
Brian D. Lehmann
@en
prefLabel
Brian D Lehmann
@ast
Brian D Lehmann
@es
Brian D Lehmann
@nl
Brian D. Lehmann
@en
P106
P21
P31
P496
0000-0003-0407-5248